Launching an Asthma Initiative Designed to Improve Asthma Management and Outcomes
To Deliver a Pilot Project on Effective Interventions to Ensure: Diagnostic Accuracy, Management of Risk and Control and Self-management for Asthma Patients.
1 other identifier
observational
33,370
0 countries
N/A
Brief Summary
Following on from a 10 year study conducted in Finland this study is designed to test the validity and sustainability of an enhanced asthma management model for the UK.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2012
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2012
CompletedFirst Submitted
Initial submission to the registry
May 14, 2014
CompletedFirst Posted
Study publicly available on registry
May 16, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2015
CompletedMay 16, 2014
May 1, 2014
2.3 years
May 14, 2014
May 14, 2014
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Exacerbations reduction
An exacerbation is defined (in line with the European Respiratory Society/American Thoracic Society guidelines) as: acute oral steroids, out of hours or Accident and Emergency (A\&E) attendance for asthma, or hospitalisation for asthma. Rationale for selecting exacerbations as the primary outcome: * They are the time of greatest risk to patients and greatest resource use * Exacerbations are defined by routinely held data, such as drug prescriptions (oral steroids and out of hours and A\&E attendance), hence are reliable when captured in primary care * Exacerbations reflect current control and future risk; a reduction in exacerbations indicates an improvement in asthmatic inflammation control and improved use of anti-inflammatory therapy
1 year
Secondary Outcomes (5)
1. Increased assessment of patients with equivocal diagnoses and reduction of diagnostic doubt (also detailed under process outcomes)
1 year
2. Hospitalisations ¬- number and rate - coded for: • Asthma • Lower respiratory conditions (including asthma), i.e. "asthma-related" events
1 year
3. Inhaled corticosteroids adherence
1 year
4. Referral rate of high-risk patients to local specialist
1 year
5. British Asthma Guideline adherence: appropriate step-wise management of patients
1 year
Other Outcomes (4)
1. Accident and Emergency (A&E) attendance
1 year
2. Proportion of patients on each asthma register that have a confirmed asthma diagnosis
1 year
3. Proportion of patients with an asthma management plan
1 year
- +1 more other outcomes
Study Arms (2)
Patients with an asthma diagnosis
Patients where there is diagnostic doubt
Eligibility Criteria
The patient questionnaire will be subject to local refinement in line with local needs, targets and priorities but will assess - * Asthma Control e.g. ACT, or ACQ or RCP3 * Lifestyle - i.e. smoking status * Comorbidities * Patient perceived adherence * Side effects The practice and patient reports will be used to characterise the patient in terms of risk and control. They will give a complete picture of the patient's asthma and will be used to identify patients for diagnostic assessment, medical management and education. Patients will then be stratified into Group 1 (patients with asthma) or Group 2 (Patients identified for further diagnostic assessment and/or with diagnostic doubt).
You may qualify if:
- Motivated and driven local champions in the area
- High rates of hospital admissions (aged 3-65)
- High asthma prevalence
- High percentage of patients who have had an asthma review in the previous 15 months.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Research in Real-Life Ltdlead
- British Lung Foundationcollaborator
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
David Price
Reasearch in Real Life Ltd
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- NETWORK
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 14, 2014
First Posted
May 16, 2014
Study Start
May 1, 2012
Primary Completion
August 1, 2014
Study Completion
August 1, 2015
Last Updated
May 16, 2014
Record last verified: 2014-05